Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Phosphodiesterase type IV (PDE4) is a member of the phosphodiesterase enzyme superfamily, which catalyzes the hydrolysis of cyclic adenosine monophosphate (cAMP) to its inactive form. PDE4 is highly specific for cAMP and plays a crucial role in regulating intracellular levels of cAMP, thereby modulating various cellular responses to hormones, neurotransmitters, and other signaling molecules. It consists of four subtypes: PDE4A, PDE4B, PDE4C, and PDE4D. It is highly expressed in immune cells, epithelial cells, and brain tissue. Therapeutic targeting focuses on selective inhibition, but adverse gastrointestinal effects remain a challenge due to broad tissue distribution.
Inhibition of PDE4 increases intracellular cAMP levels, leading to anti-inflammatory effects.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Phosphodiesterase Type IV Enzyme (PDE4).